Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Other
Sodium oxybate is a potent central nervous system (CNS) depressant primarily indicated for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy. It is the sodium salt of gamma-hydroxybutyrate (GHB).
Name
Sodium Oxybate
Raw Name
SODIUM OXYBATE
Category
Other
Drug Count
4
Variant Count
10
Last Verified
February 17, 2026
RxCUI
349482, 2636822, 2636828, 2636830, 2636832, 2636834, 2636836, 2636838, 2636840, 2698135, 2698136, 352257, 2393794, 2393795
UNII
7G33012534, 8W24SYD6ZI, G983HLV265, S8NKF3H3KT
About Sodium Oxybate
Sodium oxybate is a potent central nervous system (CNS) depressant primarily indicated for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy. It is the sodium salt of gamma-hydroxybutyrate (GHB).
Detailed information about Sodium Oxybate
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Sodium Oxybate.
Sodium oxybate is a powerful central nervous system (CNS) depressant that serves as the sodium salt of gamma-hydroxybutyrate (GHB), a naturally occurring metabolite of the neurotransmitter gamma-aminobutyric acid (GABA). Within the pharmacological landscape, sodium oxybate is classified as an orphan drug specifically designed to address the debilitating symptoms of narcolepsy, a chronic neurological disorder that impairs the brain's ability to control sleep-wake cycles.
This medication belongs to a unique therapeutic class often referred to as CNS depressants or anti-cataplectic agents. In the United States, the Food and Drug Administration (FDA) first granted approval for sodium oxybate in 2002 under the brand name Xyrem. Its approval marked a significant milestone in sleep medicine, providing the first specific treatment for cataplexy (a sudden, temporary loss of muscle tone often triggered by strong emotions). Over the years, its indications have expanded to include excessive daytime sleepiness (EDS) in both adult and pediatric patients (ages 7 and older). Because of its high potential for misuse and severe safety risks, sodium oxybate is strictly regulated under a Risk Evaluation and Mitigation Strategy (REMS) program, which ensures that only certified pharmacies and prescribers can dispense the medication.
While the exact molecular mechanism of sodium oxybate remains a subject of ongoing clinical research, it is widely understood to exert its effects through the modulation of GABA-B receptors and specific GHB-binding sites in the brain. Unlike traditional sedatives that may simply induce sleep, sodium oxybate is thought to improve the structural integrity of sleep, often referred to as "sleep architecture."
At the molecular level, sodium oxybate acts as an agonist (activator) at GABA-B receptors. These receptors are located on both presynaptic and postsynaptic neurons. By activating these receptors, the drug inhibits the release of excitatory neurotransmitters and hyperpolarizes neurons, leading to a profound depressant effect on the central nervous system. Furthermore, sodium oxybate is known to increase the duration of slow-wave sleep (Stage 3 and Stage 4 NREM sleep) and consolidate fragmented REM sleep. In patients with narcolepsy, sleep is often disorganized; by forcing the brain into a deeper, more restorative state of sleep at night, sodium oxybate helps reduce the compensatory "sleep attacks" and cataplectic episodes that occur during the day.
The pharmacokinetics of sodium oxybate are characterized by rapid absorption and an exceptionally short half-life, which necessitates a unique twice-nightly dosing schedule.
Sodium oxybate is FDA-approved for the following indications:
Off-label uses have been explored for conditions such as fibromyalgia and certain types of movement disorders, though these are not FDA-sanctioned and carry significant risks due to the drug's potent CNS-depressant properties.
Sodium oxybate is primarily available as an oral solution. It is typically supplied as a concentrated liquid (500 mg/mL) that must be diluted with water before ingestion. Because of its status as a Schedule III controlled substance (when used medically) and Schedule I (when misused), it is not available in traditional tablet or capsule forms.
> Important: Only your healthcare provider can determine if Sodium Oxybate is right for your specific condition. Due to the risks of respiratory depression and abuse, a thorough medical evaluation is required before initiation.
The standard starting dose for adults with narcolepsy is 4.5 grams per night, administered in two equal, divided doses of 2.25 grams each.
Healthcare providers may titrate (adjust) the dose upward based on efficacy and tolerability in increments of 1.5 grams per night (0.75 grams per dose) at weekly intervals. The recommended therapeutic range is typically between 6 grams and 9 grams per night. Doses exceeding 9 grams per night are generally not recommended due to the increased risk of severe CNS depression and respiratory issues.
Sodium oxybate is approved for use in pediatric patients aged 7 years and older. Unlike adult dosing, pediatric dosing is strictly weight-based.
Titration in children must be handled with extreme caution by a specialist, with adjustments occurring no more frequently than every 1 to 2 weeks.
No specific dosage adjustment is required for patients with renal impairment, as the drug is primarily metabolized to CO2. However, patients should be monitored for the high sodium load (standard sodium oxybate contains significant sodium), which may affect those with underlying kidney disease or hypertension.
In patients with hepatic (liver) impairment, the elimination half-life of sodium oxybate is significantly prolonged. The starting dose should be reduced by 50%. For example, an adult with liver cirrhosis would start at 2.25 grams per night (1.125 grams per dose).
Clinical studies have shown that elderly patients may be more sensitive to the CNS effects of sodium oxybate. Lower starting doses and slower titration are recommended to minimize the risk of falls and confusion.
If the second dose is missed, it should be skipped entirely. Do not take the second dose if you do not have at least 2 to 4 hours of remaining sleep time before your planned wake-up. Never "double up" on doses to make up for a missed one. Resume the normal schedule the following night.
An overdose of sodium oxybate is a medical emergency. Signs include severe respiratory depression (slowed breathing), profound coma, bradycardia (slow heart rate), hypothermia, and muscular hypotonia (extreme limpness). If an overdose is suspected, call 911 or emergency services immediately. Treatment is supportive, often requiring mechanical ventilation in a hospital setting.
> Important: Follow your healthcare provider's dosing instructions precisely. Do not adjust your dose or dosing schedule without explicit medical guidance from your specialist.
Sodium oxybate is associated with several common side effects that usually appear during the initial titration phase. These include:
> Warning: Stop taking Sodium Oxybate and call your doctor immediately or seek emergency care if you experience any of the following:
Prolonged use of sodium oxybate requires ongoing monitoring. Long-term effects may include:
Sodium oxybate carries a prominent FDA Black Box Warning due to two primary risks:
Report any unusual symptoms or changes in mood/behavior to your healthcare provider immediately. Regular follow-up appointments are essential to monitor for these side effects.
Sodium oxybate is a high-alert medication that requires strict adherence to safety protocols. Because it can cause rapid loss of consciousness, it must only be taken while in bed. Patients must be capable of reaching their bed within seconds of ingestion. Furthermore, the drug's high sodium content (approximately 1,100 mg to 1,600 mg per night at therapeutic doses) is a critical consideration for patients with cardiovascular or renal concerns.
Healthcare providers will typically require the following monitoring:
Patients taking sodium oxybate must not drive, operate heavy machinery, or engage in any hazardous activity requiring mental alertness for at least 6 hours after taking the second dose. Even after 6 hours, patients should ensure they feel fully awake before attempting these activities.
Alcohol is strictly prohibited. Consuming alcohol while taking sodium oxybate can lead to fatal respiratory depression. Patients must wait at least 24 hours after their last dose of sodium oxybate before consuming alcohol, and vice versa, although the safest approach is total abstinence while on this therapy.
Do not stop taking sodium oxybate suddenly without consulting your doctor. While it does not typically cause a traditional withdrawal syndrome at therapeutic doses, sudden cessation can lead to a return of severe cataplexy (rebound cataplexy) or significant insomnia. Tapering may be required in some clinical scenarios.
> Important: Discuss all your medical conditions, especially respiratory or mental health history, with your healthcare provider before starting Sodium Oxybate.
Sodium oxybate does not typically interfere with standard laboratory blood tests (such as CBC or CMP). However, it may be detected in specialized toxicology screenings for GHB. If you are undergoing a drug test, ensure the testing facility is aware of your prescription.
For each major interaction, the management strategy involves:
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter sleep aids or cold medicines.
Sodium oxybate must NEVER be used in the following circumstances:
Conditions requiring a careful risk-benefit analysis by a specialist include:
There is no known cross-sensitivity with other common drug classes (like penicillins or sulfonamides). However, patients who have had an allergic reaction to GHB or any component of the oral solution (such as malic acid used for pH adjustment) should not take the medication.
> Important: Your healthcare provider will evaluate your complete medical history, including any history of snoring, breathing problems, or mental health issues, before prescribing Sodium Oxybate.
Sodium oxybate is classified as Pregnancy Category C under the older FDA system. There are no adequate and well-controlled studies in pregnant women. Animal studies have shown some evidence of fetal harm at high doses. Sodium oxybate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is crucial for patients to discuss family planning with their neurologist, as untreated narcolepsy also poses risks during pregnancy.
Gamma-hydroxybutyrate (GHB) is a natural component of human milk. However, taking sodium oxybate significantly increases these levels. The effects on the nursing infant are not well-characterized, but there is a theoretical risk of sedation or respiratory depression in the baby. Most clinicians recommend caution or suggest formula feeding if the mother requires sodium oxybate therapy.
Sodium oxybate is FDA-approved for children aged 7 years and older for the treatment of cataplexy and EDS. It has not been studied in children under the age of 7. In pediatric patients, the drug has shown a similar safety profile to adults, though bedwetting (enuresis) and weight loss are more frequently reported. Growth should be monitored regularly in children taking this medication.
Clinical trials included a limited number of patients aged 65 and over. In general, elderly patients may be more sensitive to the effects of CNS depressants. There is an increased risk of confusion, disorientation, and falls. Physicians typically start with lower doses and titrate more slowly in this population. Monitoring for renal and cardiovascular health is also vital due to the sodium content.
While the drug's metabolism is not dependent on the kidneys, the sodium load is a concern. Each gram of sodium oxybate contains approximately 182 mg of sodium. At a 9-gram dose, this equals roughly 1,640 mg of sodium—nearly the entire daily recommended limit for some patients. Patients with Stage 4 or 5 Chronic Kidney Disease (CKD) must be monitored for fluid retention and electrolyte imbalances.
In patients with liver impairment, the clearance of sodium oxybate is reduced by approximately one-half. This leads to a doubling of the drug's half-life. A 50% reduction in the starting dose is mandatory for patients with any degree of hepatic impairment (Child-Pugh Class A, B, or C).
> Important: Special populations, particularly the elderly and those with liver disease, require individualized medical assessment and frequent monitoring during the first few months of therapy.
Sodium oxybate is a CNS depressant whose therapeutic effects for narcolepsy are mediated through GABA-B receptors and GHB receptors. It is an agonist at the GABA-B receptor, which is a G-protein coupled receptor that modulates inhibitory neurotransmission. By binding to these receptors, it decreases the release of neurotransmitters like dopamine and glutamate. Additionally, it acts on specific GHB receptors that are densely populated in the hippocampus and cortex. The net result is a consolidation of sleep stages and an increase in the duration of delta-wave sleep.
The pharmacodynamic effects are characterized by a rapid onset of sedation. Within 5 to 15 minutes of ingestion, most patients experience significant drowsiness. The duration of the sedative effect is approximately 3 to 4 hours, which is why a second dose is required to provide a full night of consolidated sleep. Over weeks of treatment, the drug reduces the frequency of cataplexy attacks and improves daytime alertness by correcting the underlying sleep fragmentation.
| Parameter | Value |
|---|---|
| Bioavailability | ~25% (Significant first-pass metabolism) |
| Protein Binding | <1% |
| Half-life | 30 to 60 minutes |
| Tmax | 0.5 to 1.25 hours (Delayed by food) |
| Metabolism | Primarily via the TCA cycle (oxidation) |
| Excretion | >90% as expired CO2; <5% Renal |
Sodium oxybate is classified as a CNS depressant and an anti-cataplectic agent. It is unique in its class, although newer formulations (like low-sodium oxybate) and mixed-salt oxybates (calcium, magnesium, potassium, and sodium oxybate) have been developed to provide the same therapeutic moiety with less sodium load.
Medications containing this ingredient
Common questions about Sodium Oxybate
Sodium oxybate is primarily used to treat two major symptoms of narcolepsy: cataplexy and excessive daytime sleepiness (EDS). Cataplexy is a sudden loss of muscle strength triggered by emotions, while EDS is the chronic struggle to stay awake during the day. The medication is approved for both adults and children aged 7 years and older. By improving the quality of sleep at night, it helps patients function better during daylight hours. It is only available through a restricted distribution program due to its potency.
The most frequently reported side effects include nausea, dizziness, headache, and bedwetting (enuresis). Many patients also experience a decrease in appetite, which can lead to weight loss over time. Some individuals may feel confused or disoriented if they wake up shortly after taking a dose. These side effects are often most prominent when first starting the medication or when the dose is increased. Most mild side effects tend to diminish as the body acclimates to the treatment.
No, you must never drink alcohol while taking sodium oxybate. Both substances are powerful central nervous system depressants, and combining them can lead to life-threatening respiratory depression, coma, or death. You should wait at least 24 hours after your last dose of sodium oxybate before having any alcohol. Conversely, if you have consumed alcohol, you must skip your sodium oxybate doses for that night. This is a critical safety rule that all patients must follow.
The safety of sodium oxybate during pregnancy has not been fully established in human clinical trials. It is currently categorized as a drug that should only be used if the potential benefits to the mother outweigh the potential risks to the developing fetus. Animal studies have suggested that high doses may cause some developmental issues. If you are pregnant or planning to become pregnant, it is essential to have a detailed discussion with your neurologist. They will help you weigh the risks of the medication against the risks of untreated narcolepsy.
Sodium oxybate works very quickly to induce sleep, often within 5 to 15 minutes of taking a dose. For this reason, it must be taken while you are sitting in bed, and you should lie down immediately. However, the long-term benefits for daytime sleepiness and cataplexy may take longer to manifest. While some patients notice an improvement within a few days, it can take several weeks or even months of consistent use and dose titration to reach the full therapeutic effect. Patience and regular communication with your doctor are key during this period.
You should not stop taking sodium oxybate suddenly without first consulting your healthcare provider. While it is not typically associated with a severe withdrawal syndrome when used as prescribed, stopping abruptly can cause a significant return of symptoms. This is known as rebound cataplexy, where muscle weakness episodes may become more frequent or severe than before treatment. Your doctor will usually provide a schedule to gradually taper the dose if you need to discontinue the medication. Always follow professional medical advice for stopping any chronic medication.
If you miss the first dose of the night, you can take it as soon as you remember, provided you have not eaten for 2 hours and still have enough time for a full night's sleep. If you miss the second dose, skip it entirely and do not take it unless you have at least 2 to 4 hours of sleep time remaining before you need to wake up. Never take two doses at once to make up for a missed one. Simply resume your regular dosing schedule the following night. Consistent timing is important for the drug's effectiveness.
Sodium oxybate is actually more commonly associated with weight loss rather than weight gain. Clinical trials have shown that a significant number of patients experience a decrease in appetite and subsequent reduction in body weight. This effect can be seen in both adults and pediatric patients. In some cases, the weight loss can be substantial, requiring monitoring by a healthcare provider. If you notice a rapid or concerning drop in weight, you should discuss this with your doctor to ensure you are maintaining proper nutrition.
Sodium oxybate has several significant drug interactions, particularly with other medications that cause sleepiness. It should not be taken with benzodiazepines, opioids, or other sedative-hypnotics. There is also a specific interaction with divalproex sodium (a seizure and mood medication) that requires a dose reduction of sodium oxybate. Always provide your doctor with a complete list of all prescriptions, over-the-counter drugs, and herbal supplements you are taking. Your pharmacist can also help check for potential interactions before you start any new medication.
Yes, a generic version of sodium oxybate oral solution was approved by the FDA and became available in recent years. This provides a more cost-effective option for many patients compared to the brand-name Xyrem. However, even the generic version is subject to the same strict REMS (Risk Evaluation and Mitigation Strategy) program requirements. This means it must still be dispensed by a certified pharmacy and prescribed by a certified healthcare provider. Your insurance provider and doctor can help determine if the generic version is appropriate for you.